The Pharmagellan Guide to Analyzing Biotech Clinical Trials

Honestly, it’s a great book. If you’re in biotech and you need a simplified overview of the intricacies of drug clinical trials and how they’re presented this is for you. It’s pretty unique in explaining statistical formulas and derivations of trial reporting as well as presenting the complexities of the the whole process. Waited a while to buy, but I’m glad I did. Worth the money if you read it cover to cover.

Book ID thorough comprehensive clearly written and easy to follow. Highly recommend it.

informative, elaborative and helpful with plenty of inlightening references.one issue I would recommend for future editions is to increase the font.

Developing new medical products is tough, and the toughest challenge may be therapeutics to treat disease. How the product performs is shared in data. Interpreting those data requires more than just college statistics, it requires insider knowledge of how clinical trials are designed, conducted, and reported. Penetrating such a vast cavern of complexity takes years, maybe decades; well now, we have a perfect guide: Analyzing Biotech Clinical Trials. Author Frank David has created a simple user manual, replete with backup sources for more information that makes a desk-side handbook for interpreting clinical data.

Pharmagellan is the single best resource to learn the rules of the road in clinical stage biotech investing. This book is comprehensive in scope and includes details that even the most experienced, professional investors need to internalize and stay current. If you aspire to be the best of the best, this is the text you need.

Great reference for anyone that's interested in analyzing clinical trial data and/or understanding potential future outcomes based on study design.

It is very useful in due dilligence or any other multi-functional appraisal project of clinical trials, but is also a fantastic and up to date book for both advanced beginners and experts looking for a reference or good reading/recall of all main aspects of clinical trials. The author states that he has reviewed hundreds of books and articles about trials but hasn't found one as integrated like this one. I agree. I have also read hundreds of such books/articles on trials and they are usually either too operational (how to file an IND, Clinical trial application, monitor a clinical site, etc) or too narrow for one function/expert in one area (e.g. statistical analysis or any particular therapeutic area details). This book is unique in that indeed is a great resource for all therapeutic areas and functions. It provides an integrated perspective useful for strategists of new clinical trials programs of all functions from regulatory to commercial, from clinical to finance. Every major issue that can come up in a multi functional analysis of a trial is stated and explained. For example even the practice of endpoint switching at the last minute by biotech start ups or others eager to demonstrate results when they only have one shot (only funds for one clinical trial) at goal is covered with recent and relevant examples. Great job. Thank you so much to the author Frank David for a resource full of great and recent examples, extensive reference list of many aspects of clinical trials and how to handle them. Importantly, although is general for every particular issue the author is well-read in all aspects of clinical trials and refers you to more detailed texts about each topic that you may need to explore further in the particular clinical trial you are organizing or analyzing.